• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

金属会影响人纤溶酶原激活物抑制剂-1 的结构和活性。二。结合亲和力和构象变化。

Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.

机构信息

Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee 37996, USA.

出版信息

Protein Sci. 2011 Feb;20(2):366-78. doi: 10.1002/pro.567.

DOI:10.1002/pro.567
PMID:21280128
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3048421/
Abstract

Human plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor with a metastable active conformation. The lifespan of the active form of PAI-1 is modulated via interaction with the plasma protein, vitronectin, and various metal ions. These metal ions fall into two categories: Type I metals, including calcium, magnesium, and manganese, stabilize PAI-1 in the absence of vitronectin, whereas Type II metals, including cobalt, copper, and nickel, destabilize PAI-1 in the absence of vitronectin, but stabilize PAI-1 in its presence. To provide a mechanistic basis for understanding the unusual modulation of PAI-1 structure and activity, the binding characteristics and conformational effects of these two types of metals were further evaluated. Steady-state binding measurements using surface plasmon resonance indicated that both active and latent PAI-1 exhibit a dissociation constant in the low micromolar range for binding to immobilized nickel. Stopped-flow measurements of approach-to-equilibrium changes in intrinsic protein fluorescence indicated that the Type I and Type II metals bind in different modes that induce distinct conformational effects on PAI-1. Changes in the observed rate constants with varying concentrations of metal allowed accurate determination of binding affinities for cobalt, nickel, and copper, yielding dissociation constants of ∼40, 30, and 0.09 μM, respectively. Competition experiments that tested effects on PAI-1 stability were consistent with these measurements of affinity and indicate that copper binds tightly to PAI-1.

摘要

人纤溶酶原激活物抑制剂 1(PAI-1)是一种丝氨酸蛋白酶抑制剂,具有亚稳的活性构象。PAI-1 活性形式的寿命通过与血浆蛋白、玻连蛋白和各种金属离子的相互作用来调节。这些金属离子分为两类:I 型金属,包括钙、镁和锰,在没有玻连蛋白的情况下稳定 PAI-1;而 II 型金属,包括钴、铜和镍,在没有玻连蛋白的情况下使 PAI-1 不稳定,但在存在玻连蛋白的情况下稳定 PAI-1。为了提供理解 PAI-1 结构和活性的异常调节的机制基础,进一步评估了这两种类型的金属的结合特性和构象效应。使用表面等离子体共振的稳态结合测量表明,活性和潜伏的 PAI-1 对固定化镍的结合均表现出低微摩尔范围内的离解常数。接近平衡的内在蛋白质荧光变化的停流测量表明,I 型和 II 型金属以不同的方式结合,对 PAI-1 产生不同的构象效应。随着金属浓度的变化观察到的速率常数的变化允许对钴、镍和铜的结合亲和力进行准确测定,得到的离解常数分别约为 40、30 和 0.09 μM。测试对 PAI-1 稳定性影响的竞争实验与这些亲和力测量结果一致,并表明铜与 PAI-1 紧密结合。

相似文献

1
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.金属会影响人纤溶酶原激活物抑制剂-1 的结构和活性。二。结合亲和力和构象变化。
Protein Sci. 2011 Feb;20(2):366-78. doi: 10.1002/pro.567.
2
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.金属影响人纤溶酶原激活物抑制剂-1 的结构和活性。I. 稳定性和蛋白酶抑制的调节。
Protein Sci. 2011 Feb;20(2):353-65. doi: 10.1002/pro.568.
3
Copper(II) Ions Increase Plasminogen Activator Inhibitor Type 1 Dynamics in Key Structural Regions That Govern Stability.铜(II)离子增加了1型纤溶酶原激活物抑制剂在决定稳定性的关键结构区域的动力学。
Biochemistry. 2016 Aug 9;55(31):4386-98. doi: 10.1021/acs.biochem.6b00256. Epub 2016 Jul 27.
4
Resolving distinct molecular origins for copper effects on PAI-1.解析铜对纤溶酶原激活物抑制因子-1作用的不同分子起源。
J Biol Inorg Chem. 2017 Oct;22(7):1123-1135. doi: 10.1007/s00775-017-1489-5. Epub 2017 Sep 14.
5
Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.纤溶酶原激活物抑制剂-1 与 vitronectin 的相互作用涉及广泛的结合表面,并诱导相互构象重排。
Biochemistry. 2009 Mar 3;48(8):1723-35. doi: 10.1021/bi8017015.
6
Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis.纤溶酶原激活物抑制剂-1不同构象形式与玻连蛋白结合的特性。对细胞周围蛋白水解调节的意义。
J Biol Chem. 1997 Mar 21;272(12):7676-80. doi: 10.1074/jbc.272.12.7676.
7
Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.纤溶酶原激活物抑制剂1含有一个隐蔽的高亲和力受体结合位点,该位点在与组织型纤溶酶原激活物形成复合物时暴露出来。
Thromb Haemost. 1998 Nov;80(5):822-8.
8
Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.1型纤溶酶原激活物抑制剂——通过蛋白水解敏感性探究潜伏型、活性型、反应中心裂解型和与纤溶酶原激活物复合型之间的构象差异。
Eur J Biochem. 1997 Sep 15;248(3):775-85. doi: 10.1111/j.1432-1033.1997.t01-1-00775.x.
9
Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.玻连蛋白上整合素依赖性细胞黏附的动力学分析——纤溶酶原激活物抑制剂-1和RGD肽的抑制潜力
Eur J Biochem. 1998 May 1;253(3):669-74. doi: 10.1046/j.1432-1327.1998.2530669.x.
10
Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.噬菌体展示的高突变纤溶酶原激活物抑制剂1(PAI-1)文库证明,潜伏期转变和蛋白酶抑制过程中PAI-1的不同结构要求。
J Mol Biol. 2001 Jan 26;305(4):773-83. doi: 10.1006/jmbi.2000.4356.

引用本文的文献

1
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1:纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
2
Dissecting molecular details and functional effects of the high-affinity copper binding site in plasminogen activator Inhibitor-1.解析纤溶酶原激活物抑制剂-1 高亲和力铜结合位点的分子细节和功能效应。
Protein Sci. 2021 Mar;30(3):597-612. doi: 10.1002/pro.4017. Epub 2021 Jan 13.
3
Resolving distinct molecular origins for copper effects on PAI-1.解析铜对纤溶酶原激活物抑制因子-1作用的不同分子起源。
J Biol Inorg Chem. 2017 Oct;22(7):1123-1135. doi: 10.1007/s00775-017-1489-5. Epub 2017 Sep 14.
4
Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.沿着反应中心环的单个荧光探针揭示了纤溶酶原激活物抑制剂-1潜伏转变过程中的位点特异性变化。
Protein Sci. 2016 Feb;25(2):487-98. doi: 10.1002/pro.2839. Epub 2015 Nov 25.
5
Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.在小鼠无缝合部分肾切除术中应用长效VLHL PAI-1可减少出血。
Biomed Res Int. 2015;2015:392862. doi: 10.1155/2015/392862. Epub 2015 Mar 26.
6
Zn2+ mediates high affinity binding of heparin to the αC domain of fibrinogen.Zn2+ 介导肝素与纤维蛋白原 αC 结构域的高亲和力结合。
J Biol Chem. 2013 Oct 11;288(41):29394-402. doi: 10.1074/jbc.M113.469916. Epub 2013 Aug 29.
7
Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.纤溶酶原激活物抑制剂-1 处于活性构象及具有正常热力学稳定性的晶体结构。
J Biol Chem. 2011 Aug 26;286(34):29709-17. doi: 10.1074/jbc.M111.236554. Epub 2011 Jun 21.
8
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.金属影响人纤溶酶原激活物抑制剂-1 的结构和活性。I. 稳定性和蛋白酶抑制的调节。
Protein Sci. 2011 Feb;20(2):353-65. doi: 10.1002/pro.568.

本文引用的文献

1
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.金属影响人纤溶酶原激活物抑制剂-1 的结构和活性。I. 稳定性和蛋白酶抑制的调节。
Protein Sci. 2011 Feb;20(2):353-65. doi: 10.1002/pro.568.
2
Tissue-type plasminogen activator-plasmin-BDNF modulate glutamate-induced phase-shifts of the mouse suprachiasmatic circadian clock in vitro.组织型纤溶酶原激活物-纤溶酶-BDNF 调节体外谷氨酸诱导的小鼠视交叉上核生物钟的相移。
Eur J Neurosci. 2009 Oct;30(8):1451-60. doi: 10.1111/j.1460-9568.2009.06946.x. Epub 2009 Oct 7.
3
Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.纤溶酶原激活物抑制剂通过一种依赖尿激酶型纤溶酶原激活物受体(uPAR)的机制调节细胞黏附。
J Cell Physiol. 2009 Sep;220(3):655-63. doi: 10.1002/jcp.21806.
4
Homeostatic and adaptive responses to zinc deficiency in Saccharomyces cerevisiae.酿酒酵母对锌缺乏的稳态和适应性反应。
J Biol Chem. 2009 Jul 10;284(28):18565-9. doi: 10.1074/jbc.R900014200. Epub 2009 Apr 10.
5
Iron homeostasis: recently identified proteins provide insight into novel control mechanisms.铁稳态:最近发现的蛋白质为新型调控机制提供了见解。
J Biol Chem. 2009 Jan 9;284(2):711-5. doi: 10.1074/jbc.R800017200. Epub 2008 Aug 29.
6
New roles for copper metabolism in cell proliferation, signaling, and disease.铜代谢在细胞增殖、信号传导及疾病中的新作用。
J Biol Chem. 2009 Jan 9;284(2):717-21. doi: 10.1074/jbc.R800055200. Epub 2008 Aug 29.
7
High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.稳定的1型纤溶酶原激活物抑制剂变体14-1B蛋白酶切割形式的高分辨率结构:用于详细相互作用研究和建模的新工具。
Protein Sci. 2008 Oct;17(10):1844-9. doi: 10.1110/ps.036707.108. Epub 2008 Aug 25.
8
PAI-1 inhibits neutrophil efferocytosis.纤溶酶原激活物抑制剂-1抑制中性粒细胞的噬菌作用。
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11784-9. doi: 10.1073/pnas.0801394105. Epub 2008 Aug 8.
9
Metal binding affinity and selectivity in metalloproteins: insights from computational studies.金属蛋白中的金属结合亲和力与选择性:计算研究的见解
Annu Rev Biophys. 2008;37:97-116. doi: 10.1146/annurev.biophys.37.032807.125811.
10
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.一种可加速纤溶酶原激活物抑制剂-1转化为无活性潜伏状态的肽。
Mol Pharmacol. 2008 Sep;74(3):641-53. doi: 10.1124/mol.108.046417. Epub 2008 Jun 17.